NASDAQ:RTRXRetrophin Stock Price, Forecast & News

Retrophin's stock was trading at $14.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RTRX stock has increased by 7.6% and is now trading at $15.91. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Retrophin.

Retrophin is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Retrophin.

Retrophin Inc (NASDAQ:RTRX) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.68) by $0.70. The biopharmaceutical company had revenue of $47.77 million for the quarter, compared to the consensus estimate of $43.14 million. Retrophin had a negative net margin of 57.01% and a negative return on equity of 43.15%. View Retrophin's earnings history.

7 analysts have issued 12 month target prices for Retrophin's shares. Their forecasts range from $19.00 to $34.00. On average, they expect Retrophin's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 79.1% from the stock's current price. View analysts' price targets for Retrophin.

Media headlines about RTRX stock have trended very positive on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Retrophin earned a news impact score of 3.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutRetrophin.

Some companies that are related to Retrophin include Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX) and Passage Bio (ZNTL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Retrophin investors own include CVS Health (CVS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), Dynavax Technologies (DVAX), Heron Therapeutics (HRTX) and ImmunoGen (IMGN).

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

Retrophin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.65%), The Manufacturers Life Insurance Company (5.43%), State Street Corp (4.00%), Nuveen Asset Management LLC (1.30%), Assenagon Asset Management S.A. (1.00%) and Deutsche Bank AG (0.97%). Company insiders that own Retrophin stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View institutional ownership trends for Retrophin.

RTRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, RA Capital Management L.P., DRW Securities LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Legal & General Group Plc, and UBS Group AG. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Steve Aselage, and William E Rote. View insider buying and selling activity for Retrophin.

RTRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Janus Henderson Group PLC, GW&K Investment Management LLC, Atom Investors LP, AXA, Russell Investments Group Ltd., Dupont Capital Management Corp, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Retrophin.

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RTRX stock can currently be purchased for approximately $15.91.

Retrophin has a market capitalization of $686.61 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Retrophin employs 214 workers across the globe.

The official website for Retrophin is www.retrophin.com.

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]